David Suhy

Biography
David is that unique combination of gene therapy expert, experienced in bio ventures both private and public, having brought gene therapy ideas from white board through to Phase 2 clinical trials, and being great leader that science teams love to work with. All three come in handily at Earli.Before Earli mission, he was the CSO at Benitec Biopharma with expertise in combining multiple therapeutic modalities (RNAi, antisense RNA, proteins) with gene therapy delivery, and oversaw development path for multiple clinical products including those for Hepatitis C Virus (HCV), Head and Neck Squamous Cell Carcinoma (HNSCC) and Oculopharyngeal Muscular Dystrophy (OPMD). He developed the first virally encoded, systemic RNAi compound used clinically in human subjects. He has held previous scientific leadership roles at Tacere Therapeutics, Takara Bio, Anatara Biosciences and PPD. He holds a PhD in Biochemistry, Molecular Biology and Cell Biology from Northwestern University and completed his postdoctoral training at Stanford.

---

Talk
Turn Cancer Against Itself
Imagine there was a way to move from systemic cancer treatment with massive on-target off tumor effects to synthetic genetic switches that ONLY turn on INSIDE cancer cells. Once activated, the switches genetically force the cancer cells to produce their own therapy against themselves, from cytokines to TCEs to multi-specifics.

AI and Data Sciences Showcase:
IntoDNA
Earli addresses pharma’s priority goal: high therapeutic index. Earli will be in Phase 1 in 15 months. SAB includes Jim Allison, Bob Langer, Phil Greenberg, Bill Hait, Amy Abernethy, Alan Ashworth. Earli has raised $104M; Board includes a16z, Khosla, and former J&J CEO Alex Gorsky. The founders are successful experienced entrepreneurs (prior exit >$250M).